PDRN Benefits and Side Effects
What the research supports, what is marketing, and what to watch for
PDRN is marketed for everything from wound healing to wrinkle reduction to hair regrowth. Some of those claims rest on real clinical research; some rest on a cell-culture study and a good press release. This page separates them, states the evidence strength for each, and covers side effects and who should avoid PDRN.
Benefits with real evidence (injectable)
When PDRN is injected into the dermis by a clinician, it reaches living tissue directly and the mechanisms described on our what-is-PDRN page can operate. This is where the clinical literature lives.
Wound healing and tissue repair Strongest
PDRN's longest-standing medical use is accelerating wound healing — including chronic and hard-to-heal wounds such as diabetic foot ulcers and pressure sores. Multiple clinical studies support faster closure and improved tissue quality versus control. This is the claim with the deepest evidence base, and it is a medical use, not a cosmetic one.
Skin rejuvenation and quality Moderate
Injectable PDRN/PN "skin boosters" (the Rejuran family) show improvements in skin elasticity, hydration, fine lines and overall texture in clinical settings, and are a routine aesthetic procedure in Korea. Evidence is positive but smaller and less standardised than the wound-healing literature.
Post-procedure recovery and anti-inflammation Moderate
Because of its anti-inflammatory and repair-promoting profile, injectable PDRN is used to calm skin and speed recovery after laser, microneedling and similar procedures.
Scars, hair, and other uses Early / limited
Claims around scar improvement, hair regrowth and under-eye rejuvenation exist and are biologically plausible given the mechanism, but human evidence is thin, small-scale or preliminary. Treat these as promising-but-unproven.
Benefits claimed for topical products
Serums, creams, masks and patches face the skin-barrier problem: DNA fragments are large molecules and the stratum corneum is designed to keep them out. Independent human trials showing that topical PDRN activates dermal A2A receptors at meaningful levels are lacking.
That does not make topical PDRN products useless — it changes what you should expect:
- Hydration and barrier support. Most PDRN cosmetics are well-formulated moisturisers with humectants, ceramides or peptides. They hydrate and support the barrier reliably — because of those ingredients as much as the PDRN.
- Soothing. The anti-inflammatory story makes PDRN a reasonable fit for calming irritated skin, and users commonly report a comfortable, non-irritating feel.
- Gradual texture/firmness improvements. Plausible over months from the collagen-support story, but this is exactly the claim with the weakest topical evidence. Do not expect injectable-grade results from a jar.
Buy a topical PDRN product because it is a good moisturiser with a sensible supporting formula and a texture you like — not because you expect it to regenerate your dermis. The regeneration claim belongs to the injectable, performed by a clinician.
Side effects and safety
Injectable PDRN
As a medical procedure, injectable PDRN carries the usual injection risks plus its own profile:
- Transient redness, swelling, bruising, tenderness and small bumps at injection sites — common and self-limiting.
- Rarely, infection, nodules or allergic reaction — which is why it must be done by a licensed clinician with sterile technique.
- Downtime of a few days is typical.
Topical PDRN
Topical PDRN is considered low-risk. Reported issues are the ordinary ones for any cosmetic:
- Mild irritation, stinging or contact reaction in sensitive individuals — usually from a co-ingredient (fragrance, a strong active like retinal) rather than the PDRN itself.
- Breakouts if a rich cream does not suit your skin type.
Patch-test any new product on the inner forearm for 24–48 hours before full-face use, and introduce one new active at a time so you can attribute any reaction.
Who should avoid or be cautious
- Fish / salmon allergy. PDRN is salmonid-derived. Although purification removes proteins, caution is warranted; discuss with a clinician and patch-test carefully.
- Pregnancy and nursing. There is not enough safety data; most clinicians advise avoiding both injectable and, prudently, high-concentration topical PDRN.
- Active skin infection, open wounds or uncontrolled inflammatory skin disease on the treatment area — do not apply or inject over compromised skin.
- Anyone combining with strong actives (retinoids, acids) — layering can increase irritation; alternate rather than stack, especially at first.
Injectable PDRN is a medical procedure. It should only be performed by a licensed, experienced clinician using approved products. This site does not recommend self-injection or unregulated sources under any circumstances.
PDRN vs. collagen, HA, retinol, peptides, exosomes
Quick orientation on how PDRN fits among the actives it is usually compared to:
| Active | Primary job | How PDRN differs |
|---|---|---|
| Collagen | Topical collagen mostly hydrates; it does not rebuild your collagen. | PDRN aims to stimulate your fibroblasts to make collagen, rather than supplying collagen as an ingredient. |
| Hyaluronic acid | Pure hydration — binds water in the skin. | Complementary, not competitive. HA hydrates; PDRN targets repair signalling. Many formulas combine both. |
| Retinol / retinal | The gold standard for cell turnover, fine lines, acne — strong evidence. | Different mechanism and stronger evidence base than topical PDRN. PDRN is gentler and often paired with retinoids to offset irritation. |
| Peptides | Signal molecules for collagen/repair; modest, formulation-dependent effects. | Conceptual cousins — both are "signalling" ingredients. PDRN's A2A-receptor story is more specific; peptides are more varied. |
| Exosomes | Vesicle-based signalling; the newer, even-hype-ier category. | Exosome evidence in cosmetics is thinner and regulation murkier than PDRN's. PDRN at least has an injectable clinical history. |
For the product-level comparisons, see our round-ups of the best PDRN serums and best PDRN creams.
Frequently Asked Questions
What are the proven benefits of PDRN?
The strongest evidence is for injectable PDRN in wound healing, including chronic wounds like diabetic foot ulcers. Injectable PDRN also shows moderate evidence for skin rejuvenation and post-procedure recovery. Topical PDRN benefits are less certain and are mostly hydration, barrier support and soothing.
What are the side effects of PDRN?
Topical PDRN is low-risk: occasional mild irritation or breakouts, usually from a co-ingredient. Injectable PDRN causes temporary redness, swelling, bruising and tenderness at injection sites, and rarely infection or allergic reaction, which is why it must be performed by a licensed clinician.
Who should avoid PDRN?
People with fish or salmon allergies should be cautious since PDRN is salmonid-derived. Those who are pregnant or nursing should avoid it due to limited safety data. Do not apply or inject PDRN over active infection, open wounds or uncontrolled inflammatory skin disease.
Is PDRN better than retinol or hyaluronic acid?
They do different jobs. Retinol has the strongest evidence for cell turnover and fine lines. Hyaluronic acid is a pure hydrator. PDRN targets repair signalling and is gentler, so it is often paired with retinoids or HA rather than replacing them.
Can PDRN regrow hair or fade scars?
These uses are biologically plausible and appear in early research, but human evidence is thin and preliminary. Treat hair-regrowth and scar-fading claims for PDRN as promising-but-unproven rather than established.
References & Sources
- Galeano M, et al. Pharmaceuticals (2021) — Wound-healing review: adenosine A2A receptor activation and the nucleotide salvage pathway.
- Squadrito F, et al. J Clin Endocrinol Metab (2014) — Strongest human RCT for injectable PDRN (diabetic foot ulcers).
- Lampridou S, et al. J Cosmet Dermatol (2025) — Systematic review of aesthetic polynucleotide injections: 9 low/moderate-quality studies, 219 patients. Two authors tied to PN manufacturers.
- Alhussain AM, et al. Cureus (2026) — Systematic review of RCTs (7 trials, 183 participants); no serious treatment-related adverse events.
- Kim MS, et al. Medicine (2019) — Meta-analysis: intra-articular PDRN beat hyaluronic acid for knee-OA pain at 1–2 months only.
- De Caridi G, et al. Int Wound J (2016) — Topical polynucleotide gel on debrided venous leg ulcers (60% vs 22% complete healing).
- Bos JD, Meinardi MM. Exp Dermatol (2000) — the 500 Dalton rule — Intact stratum corneum effectively blocks molecules above ~500 Da — PDRN is far larger.
- Ye R, et al. PLoS One (2026) — Small split-face topical PDRN-vs-retinol trial; authors employed by cosmetic R&D firms (declared no conflicts). Treat as preliminary.
- Kim HM, et al. Molecules (2022) — Topical PDRN in UVB-irradiated animals delivered via microneedling (barrier mechanically breached) — not plain rub-on evidence.